Pulmonary arterial hypertension (PAH) is a progressive disease that can cause ventricular failure and death. This report provides insights on the treatment patterns of PAH patients, their comorbidities and related healthcare costs. Our findings are based on a longitudinal study of up to four years of commercial health insurance claims. These insights may supplement currently available evidence to better inform payers, providers, patients, patient advocates, and policymakers, and may also encourage payer organizations to explore their own data.

This report was commissioned by Actelion Pharmaceuticals.